Влезте в профила си за пълен достъп до възможностите на Eclipse.
Вход
Каталог "Библиографии"
| Списание
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
Ludwig, H., Goranova-Marinova, V., al., e. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup,
, .
Ludwig, H., Goranova-Marinova, V., al., e. .
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
: , .
Ludwig, H., Goranova-Marinova, V., al., e. ()
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup,
:
Ludwig, H.,
Goranova-Marinova, V., &
al., e.
().
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia and Lymphoma; Leukemia and Lymphoma.